Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$2.99 +0.99%

+$0.04 today

Market cap
$310.61M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.38M

Average 1.73M

Returns on capital

Larimar Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-212.2%

avg 240.7%

ROIC

-210.0%

avg 294.2%

ROA

-113.6%

avg -86.6%

Analysis

ROA is currently the strongest return metric at -113.6% versus its period average of -86.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Carole S. Ben-Maimon

CEO & DirectorUSD 976.4K67——

Michael Celano

Secretary & Chief Financial OfficerUSD 697K67234.25K0.27%

Gopi Shankar

Chief Development OfficerUSD 642.35K5581.44K0.10%

Russell G. Clayton

Chief Medical Officer—65——

Francis Michael Conway

Vice President & Controller————

John Berman

Vice President of Finance & Administration————

John Harlow Jr.

President & COO—50——

Jennifer Spokes Johansson

Vice President of Legal & Compliance————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

15

$26.10M

Sells

0

$0.00

Net Transaction Value

+$26.10M

Net buying

Most Active

Flynn James E

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Hamilton Thomas Edward

Indirect

Buy$187.1K
Nov 11, 26

BEN-MAIMON CAROLE

Direct

Buy$50K
Nov 11, 26

THOMAS FRANK E

Direct

Buy$21.8K
Nov 11, 26

Truitt Joseph

Direct

Buy$9.8K
Nov 11, 26

Harlow John B. Jr.

Direct

Buy$49.9K
Nov 11, 26

Celano Michael

Direct

Buy$50K
Nov 11, 26

Shankar Gopi

Direct

Buy$13.5K
Jul 6, 26

Hamilton Thomas Edward

Direct

Buy$166.9K
Feb 27, 26

Flynn James E

Indirect

Buy$5.4M
Feb 27, 26

Flynn James E

Indirect

Buy$5.4M

1–10 of 15

Summary

Insiders reported 15 buys worth $26.10M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $26.10M. Flynn James E was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Larimar Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LRMR's management, answered from reported figures.

Who manages LRMR?

Larimar Therapeutics, Inc. (LRMR) lists 8 active executives. The top listed executive is Carole S. Ben-Maimon, CEO & Director.

Are LRMR insiders buying or selling?

Recent insider activity shows net buying of $192.35M.